August 06, 2020
The final data of a personalized tumor lysate, particle-loaded, dendritic cell vaccine demonstrated that patients with stage III or IV melanoma with high-risk of recurrence after complete surgical resection had better survival benefit and disease-free survival rate with the vaccine over placebo, according to a press release from Elios Therapeutics.
July 30, 2020
The FDA granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600E-mutated advanced melanoma.
July 27, 2020
The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab plus ipilimumab under 2 melanoma indications.
July 26, 2020
A guideline from the American Society of Clinical Oncology addresses 4 clinical questions regarding approaches to systemic treatment for different types and stages of melanoma, in addition to summarizing the trials on which the recommendations were based.
July 23, 2020
In an interview with Targeted Oncology, following the tweet chat, Shoushtari highlighted the key takeaways from the tweet chat discussion and spoke to how he would make his own treatment decisions for this patient scenario.
July 21, 2020
Christian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.
July 17, 2020
A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.
July 17, 2020
The phase 2 basket arm trial of IDE196 in patients with solid tumors harboring GNAQ or GNA11 hotspot mutations has met its clinical protocol criteria for cohort expansion.
June 27, 2020
In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.
June 23, 2020
Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.